Tristel, the Suffolk based supplier of infection and contamination control products, announced that final results to June 2011 showed sales of £9.3 million (2010: £8.8 million), adjusted operating profit of £824,000 (2010: £1.7 million), pre-tax profit of £508,000 (2010: £1.7 million), EPS of 1.21p (2010: 3.67p) and DPS of 0.56p (2010: 1.825p). The results include exceptional items of £nil (2010: £233,000 credit).
The company reported that sales comprised Hospital Infection Control, £7.2 million (2010: £7.1 million) and Animal healthcare £2.1 million (2010: £1.6 million). The first sales of Crystel products (£38,000) were made, with very significant growth expected in 2011/12. Export sales were £1.0 million (2010: £748,000). Gross margin was 63.5% (2010: 64.4%) and year end net cash was £441,000.
Q1 2011/12 trading is ahead of board expectations.
It was also anounced that Christopher Samler has been appointed as Independent Non-Executive Director.
The TSTL share price has decreased by 27% over the last year.
Tristel Plc is graded b by LCF Research. To learn more, follow the link.
